This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
The overall mortality rate for U.S. patients with cardiovascular disease has improved significantly in recent years. At the same time, however, care gaps remain that must be addressed.
As long as the influencer presents with apparent knowledgeability, a polished appearance, medical accoutrements and a caring demeanor, he or she will probably be afforded plenty of leeway to hold forth on all things health and healthcare.
In an update to an early alert from May, the U.S. Food and Drug Administration said an investigation by the device manufacturer concluded the black spots were part of the PVC material used in manufacturing.
Utah’s Office of Artificial Intelligence Policy will allow patients to use a dermatology app to diagnose and get prescription treatments for acne. More serious skin conditions will be referred to a licensed physician.
Hospitals should be making every effort to help sonographers deliver better, more accurate echocardiograms and improve the diagnosis of severe aortic stenosis. If you take care of your sonographers, your sonographers will take care of you.
Valve-in-valve TAVR outperforms redo SAVR for the first six months after treatment, according to a new meta-analysis published in the American Journal of Cardiology. Then, however, things begin to shift.
At a time when patient assaults against nurses are reportedly on the rise, cases that invert the equation only reinforce the public’s perception that hospitals are chaotic places.
“We can reach tissues, bones and organs with high spatial precision that haven’t been reachable with light-based printing methods," one researcher explained.
The popular SGLT2 inhibitor, sold under the brand name Farxiga, is approved by the FDA to treat heart failure, type 2 diabetes and CKD. Recent data on its ability to affect the symptoms of heart failure patients have been inconsistent.
In its annual outlook report released this week, Fitch Ratings says the coming calendar year will probably strike much of the sector as “another make or break” period.